Welcome to our dedicated page for Sinovac Biotech news (Ticker: SVA), a resource for investors and traders seeking the latest updates and insights on Sinovac Biotech stock.
Sinovac Biotech Ltd (SVA) is a leading biopharmaceutical company focused on developing vaccines for infectious diseases including hepatitis, influenza, and COVID-19. This page provides investors and healthcare professionals with centralized access to official company announcements, financial disclosures, and operational updates.
Track critical developments through verified press releases covering clinical trial results, regulatory approvals, and manufacturing expansions. Our curated news collection includes earnings reports, partnership announcements, and analysis of Sinovac's role in global immunization programs.
Key content categories include vaccine research updates, government collaboration news, and financial performance reports. Bookmark this page for real-time insights into Sinovac's progress in addressing public health challenges through innovative biopharmaceutical solutions.
SINOVAC Biotech Ltd. (NASDAQ: SVA) has signed an advance purchase agreement with Gavi for up to 380 million doses of its COVID-19 vaccine, CoronaVac®, to be distributed through the COVAX Facility. Initial supply will include 50 million doses by September 2021, with options for an additional 330 million doses in subsequent quarters. The vaccine has received WHO Emergency Use Listing and demonstrated effectiveness in recent studies, preventing 83.5% of symptomatic cases according to a phase III trial. This agreement enhances global vaccine accessibility amid ongoing pandemic efforts.
Sinovac Biotech Ltd. (NASDAQ: SVA) reported positive outcomes from Phase I/II clinical trials of its COVID-19 vaccine, CoronaVac®, published in The Lancet Infectious Diseases. The double-blind study involved 552 healthy participants aged 3-17, showing CoronaVac to be safe and effective. After two doses, seroconversion rates were 100% in some age groups, with stronger immune responses in children compared to adults. The findings support further studies for broader immunization strategies.
SINOVAC Biotech Ltd. (NASDAQ: SVA) announced that its COVID-19 vaccine, CoronaVac®, received emergency use approval from the World Health Organization (WHO). Previously, the Strategic Advisory Group of Experts on Immunization (SAGE) recommended the vaccine for adults aged 18 and older in a two-dose regimen. The WHO's Emergency Use Listing expedites vaccine availability during health emergencies. Furthermore, the European Medicines Agency (EMA) has begun a rolling review for potential EU approval. SINOVAC has supplied over 600 million doses globally, solidifying its role as a leading supplier of COVID-19 vaccines.
Sinovac Biotech Ltd. (NASDAQ: SVA) has filed its 2020 annual report with the SEC, reporting significant growth. In Q4 2020, sales reached $327.5 million, up from $81.1 million year-over-year. Full-year sales totaled $510.6 million, doubling from $246.1 million in 2019. Net income for Q4 was $107.3 million ($1.09 per share), compared to $21.7 million in the prior year. The company also highlighted successful vaccine development, with over 200 million doses of CoronaVac delivered worldwide.
Sinovac Biotech Ltd. (NASDAQ: SVA) announced the completion of its third production line for CoronaVac®, enhancing its annual vaccine capacity to 2 billion doses. Over 200 million doses have been delivered to more than 20 countries, with over 100 million administered globally. The production line complies with stringent quality standards and has received emergency use approval from over 30 countries. Sinovac aims to continue expanding production and research for CoronaVac®, contributing to global vaccine availability and affordability.
Sinovac Biotech Ltd. (NASDAQ: SVA) announced an amendment to its shareholder rights plan, extending its expiration date from February 22, 2021, to February 22, 2022. This change is significant as it might influence shareholder protection during potential takeover bids. Sinovac, known for its biopharmaceutical products, is actively involved in creating and marketing various vaccines including those for hepatitis, influenza, and COVID-19. The company is also pursuing international market authorization for its products, which could enhance its growth prospects.
Sinovac Biotech Ltd. (NASDAQ:SVA) announced that the China National Medical Products Administration has granted conditional marketing authorization for CoronaVac, its COVID-19 vaccine for adults. This decision follows extensive submissions and rolling reviews by the NMPA since September 2020. Sinovac has completed over 40 submissions and applied for conditional marketing authorization on February 3, 2021, based on phase III trial data. The approval is pivotal for Sinovac's goal of increasing vaccine availability worldwide as it seeks additional regulatory approvals in multiple countries.
Sinovac Biotech Ltd. (NASDAQ: SVA) announced Phase III results for its COVID-19 vaccine, CoronaVac, following trials in Brazil, Turkey, Indonesia, and Chile. The trials enrolled 25,000 participants, showing an efficacy rate of 50.65% for all cases and 83.70% for cases requiring medical treatment. In Turkey’s second trial stage, the efficacy rate was 91.25% after vaccination. Sinovac has filed for conditional market authorization with China’s NMPA and is actively pursuing regulatory approval in additional countries to enhance global vaccine accessibility.
Sinovac Biotech Ltd. (NASDAQ: SVA) has filed for conditional market authorization for its COVID-19 vaccine, CoronaVac, with China's National Medical Products Administration (NMPA). Preliminary results from phase III clinical studies indicate a favorable safety profile for the vaccine, achieving efficacy standards set by the World Health Organization and NMPA. Sinovac anticipates this authorization will enhance its market presence and facilitate international growth in the biopharmaceutical sector.
Sinovac Biotech Ltd. (NASDAQ:SVA) has received regulatory approval from the China National Medical Products Administration for its 23-Valent Pneumococcal Polysaccharide vaccine. This vaccine aims to prevent infections caused by Streptococcus pneumoniae in adults and children aged two and above. Initiated in 2009, the vaccine's development was completed through multiple phases, including a Phase III study that demonstrated its safety and effectiveness. This approval marks a significant milestone as Sinovac's first bacterial vaccine, enhancing its product portfolio.
